2 million new cases in 2008.

Worldwide, colorectal cancer is the third most common cancer in men and the second most common diagnoses among women with more than 1.2 million new cases in 2008. Colon cancer is one of the deadliest cancers and was responsible for more than 600,000 deaths alone in 2008. In Europe, the overall survival rate is 43 %, while in the United States 62 %, these numbers drop considerably when the cancer spreads to distant organs themselves. The risk of colon cancer increases with age – in developed countries, more than 90 % of in persons in individuals over 50 years old.

Sanofi Oncology and Regeneron will collaborate on a broad oncology development program, combining the investigational agent ZALTRAP with common chemotherapy regimens in the treatment of patients with advanced cancer. In addition to VELOUR, the program includes a Phase III trial and a Phase II trial, both of which are fully enrolled:.Flexibility and adaptability. Boston Scientific’s Express LD Iliac stent system ofBoston Scientific Corporation in today announced that the U.S. Food and Drug Administration approved expression LD Iliac stent system designed to the pre – applications in iliac arteries. To Express LD Iliac Stent is the the first and only low-profile premounted , balloon stent admitted approved by the FDA for the use in of treating iliac artery disease. Company said it planned to start the product immediately the United States..